We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Biogen didn't have much success on the market with multiple sclerosis med Zinbryta, and now the drug is at the center of a discrimination and retaliation lawsuit by a former manager.
The Agency’s Pharmacovigilance Risk Assessment Committee (PRAC) has confirmed that Zinbryta (daclizumab) “poses a risk of serious and potentially fatal immune reactions affecting the brain, liver and other organs.”